Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, induces superior reductions in total body fat and liver fat compared with placebo and active controls in type 2 diabetes and metabolic-associated steatotic liver disease (MASLD).
Lean mass loss is proportionate to weight loss, aligning with other anti-obesity therapies, alleviating concerns regarding excessive lean mass reduction.
Retatrutide demonstrates robust improvements in metabolic parameters, including insulin sensitivity and lipid metabolism, with an acceptable safety profile.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
